CoChat
Sign Up
Cited by 76

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Recent Studies and Progress in the Intratumoral Administration of Nano-Sized Drug Delivery Systems

Yun, Wan Su, Kim, Jeongrae, Lim, Dong-Kwon, Kim, Dong-Hwee, Jeon, Seong Ik, Kim, Kwangmeyung·2023·Nanomaterials
DOI 10.3390/nano13152225PMC PMC10421122
Open this paper in CoChat — free account

Abstract

Over the last 30 years, diverse types of nano-sized drug delivery systems (nanoDDSs) have been intensively explored for cancer therapy, exploiting their passive tumor targetability with an enhanced permeability and retention effect. However, their systemic administration has aroused some unavoidable complications, including insufficient tumor-targeting efficiency, side effects due to their undesirable biodistribution, and carrier-associated toxicity. In this review, the recent studies and advancements in intratumoral nanoDDS administration are generally summarized. After identifying the factors to be considered to enhance the therapeutic efficacy of intratumoral nanoDDS administration, the experimental results on the application of intratumoral nanoDDS administration to various types of cancer therapies are discussed. Subsequently, the reports on clinical studies of intratumoral nanoDDS administration are addressed in short. Intratumoral nanoDDS administration is proven with its versatility to enhance the tumor-specific accumulation and retention of therapeutic agents for various therapeutic modalities. Specifically, it can improve the efficacy of therapeutic agents with poor bioavailability by increasing their intratumoral concentration, while minimizing the side effect of highly toxic agents by restricting their delivery to normal tissues. Intratumoral administration of nanoDDS is considered to expand its application area due to its potent ability to improve therapeutic effects and relieve the systemic toxicities of nanoDDSs.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/nano13152225

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Figures

Scheme 1 Schematic illustration of intratumoral nanoDDS administration. Various types of nanoDDSs can be administered intratumorally for different therapeutic approaches, enhancing their tumor-specific accumulation and diminishing off-target delivery.
Scheme 1 Schematic illustration of intratumoral nanoDDS administration. Various types of nanoDDSs can be administered intratumorally for different therapeutic approaches, enhancing their tumor-specific accumulation and diminishing off-target delivery.CC BY · PubMed Central
Scheme 2 External factors affecting the intratumoral distribution of intratumorally administered nanoDDSs. To achieve maximal therapeutic outcomes, intratumorally administered nanoDDSs should be uniformly distributed throughout the tumor tissue without any intravasation or washout. Therefore, external factors affecting the intratumoral distribution of nanoDDSs, such as particle size, surface charge and functionalization, and injection site and rate, should be precisely regulated.
Scheme 2 External factors affecting the intratumoral distribution of intratumorally administered nanoDDSs. To achieve maximal therapeutic outcomes, intratumorally administered nanoDDSs should be uniformly distributed throughout the tumor tissue without any intravasation or washout. Therefore, external factors affecting the intratumoral distribution of nanoDDSs, such as particle size, surface charge and functionalization, and injection site and rate, should be precisely regulated.CC BY · PubMed Central
Figure 1 Intratumoral-nanoDDS-administration-mediated chemotherapy. (A) Thermosensitive polymeric micelles loaded with both cisplatin and paclitaxel were prepared for intratumorally administered chemotherapy. (B) Thermosensitive polymeric micelles underwent a phase transition to a gel state. (C) The cumulative release profiles of cisplatin and paclitaxel were observed. (D) The tumor size changes after intratumoral administration of polymeric micelles were measured over time. Reproduced with permission [104]. Copyright 2017, ACS Publications. (E) The microneedle-mediated intratumoral administration of cisplatin-encapsulated nanoparticles was proposed. (F) The sizes and (G) weights of tumors with microneedle-mediated administration were significantly regressed compared to those with intravenous and instant intratumoral administrations. *** p < 0.05. Reproduced with permission [106]. Copyright 2018, ACS Publications.
Figure 1 Intratumoral-nanoDDS-administration-mediated chemotherapy. (A) Thermosensitive polymeric micelles loaded with both cisplatin and paclitaxel were prepared for intratumorally administered chemotherapy. (B) Thermosensitive polymeric micelles underwent a phase transition to a gel state. (C) The cumulative release profiles of cisplatin and paclitaxel were observed. (D) The tumor size changes after intratumoral administration of polymeric micelles were measured over time. Reproduced with permission [104]. Copyright 2017, ACS Publications. (E) The microneedle-mediated intratumoral administration of cisplatin-encapsulated nanoparticles was proposed. (F) The sizes and (G) weights of tumors with microneedle-mediated administration were significantly regressed compared to those with intravenous and instant intratumoral administrations. *** p < 0.05. Reproduced with permission [106]. Copyright 2018, ACS Publications.CC BY · PubMed Central
Figure 2 Immune activation by PTT with intratumorally administered nanoDDSs. (A) The intratumoral administration of Au@Se NPs and NIR irradiation simultaneously induced the ICD by PTT and dendritic cell activation, enhancing antitumor immunity. (B) The maturation of dendritic cells and activation of CD8+ and CD4+ T cells were demonstrated after PTT with intratumorally administered Au@Se NPs. ** p < 0.01, *** p < 0.001. (C) The treatment with Au@Se NPs successfully inhibited the growth of both primary and distant tumors. Reproduced with permission [109]. Copyright 2020, Elsevier.
Figure 2 Immune activation by PTT with intratumorally administered nanoDDSs. (A) The intratumoral administration of Au@Se NPs and NIR irradiation simultaneously induced the ICD by PTT and dendritic cell activation, enhancing antitumor immunity. (B) The maturation of dendritic cells and activation of CD8+ and CD4+ T cells were demonstrated after PTT with intratumorally administered Au@Se NPs. ** p < 0.01, *** p < 0.001. (C) The treatment with Au@Se NPs successfully inhibited the growth of both primary and distant tumors. Reproduced with permission [109]. Copyright 2020, Elsevier.CC BY · PubMed Central
Figure 3 PDT with intratumorally administered Mal-PEG-TiO2-UCN nanoparticles. (A) A TEM image of synthesized Mal-PEG-TiO2-UCNs was obtained. (B) The UCNs shifted the wavelength of irradiated light to 450~475 nm, and the TiO2 shell absorbed the shifted light to produce ROSs. (C) The Mal-PEG-TiO2-UCNs effectively generated ROSs even inside the deep tissue phantoms. * p < 0.05. (D) The intratumoral administration of Mal-PEG-TiO2-UCN with 980 nm light irradiation significantly suppressed tumor growth (E) without causing any notable side effects. Reproduced with permission [110]. Copyright 2015, ACS Publications.
Figure 3 PDT with intratumorally administered Mal-PEG-TiO2-UCN nanoparticles. (A) A TEM image of synthesized Mal-PEG-TiO2-UCNs was obtained. (B) The UCNs shifted the wavelength of irradiated light to 450~475 nm, and the TiO2 shell absorbed the shifted light to produce ROSs. (C) The Mal-PEG-TiO2-UCNs effectively generated ROSs even inside the deep tissue phantoms. * p < 0.05. (D) The intratumoral administration of Mal-PEG-TiO2-UCN with 980 nm light irradiation significantly suppressed tumor growth (E) without causing any notable side effects. Reproduced with permission [110]. Copyright 2015, ACS Publications.CC BY · PubMed Central
Figure 4 Hypoxia alleviation and PDT by PCM-224-Pt. (A) PCM-224-Pt was synthesized via the in situ growth of Pt nanozymes on the PCN-224 MOFs. (B) Pt nanozyme produced oxygen from H2O2, and the oxygen was converted into ROSs by PCN-224 inside cancer cells. (C) The synthesized PCM-224-Pt was observed with TEM. (D) PCM-224-Pt exhibited high toxicity in both hypoxic and normoxic conditions, whereas the cytotoxicity of PCN-224 was diminished in hypoxia. (E) When PCN-224-Pt was intratumorally administered, it greatly promoted tumor regression by alleviating tumor hypoxia and enhancing the effect of PDT. ** p < 0.01. Reproduced with permission [112]. Copyright 2018, ACS Publications.
Figure 4 Hypoxia alleviation and PDT by PCM-224-Pt. (A) PCM-224-Pt was synthesized via the in situ growth of Pt nanozymes on the PCN-224 MOFs. (B) Pt nanozyme produced oxygen from H2O2, and the oxygen was converted into ROSs by PCN-224 inside cancer cells. (C) The synthesized PCM-224-Pt was observed with TEM. (D) PCM-224-Pt exhibited high toxicity in both hypoxic and normoxic conditions, whereas the cytotoxicity of PCN-224 was diminished in hypoxia. (E) When PCN-224-Pt was intratumorally administered, it greatly promoted tumor regression by alleviating tumor hypoxia and enhancing the effect of PDT. ** p < 0.01. Reproduced with permission [112]. Copyright 2018, ACS Publications.CC BY · PubMed Central
Figure 5 Intratumoral-administration-mediated combined cancer immunotherapy. (A) The intratumorally administered ZGd-NRs for combination therapy were supposed to release Zol and Gd3+, which depletes TAMs and induces RT-based ICD, respectively, leading to antitumor immunity activation. ZGd-NRs exhibited significant toxicity to both (B) cancer cells and (C) TAMs. (D) The intratumorally administered ZGd-NRs remained inside tumor tissues for a much longer time than the free ICGs (red dot circle and D: distant tumors, P: primary tumors). (E) The intratumoral administration of ZGd-NRs showed higher anticancer efficacy compared to the administration of Zol or Gd3+ alone, demonstrating the effectiveness of combination therapy. N.S. not significant, * p < 0.05, *** p < 0.001. Reproduced with permission [115]. Copyright 2017, ACS Publications.
Figure 5 Intratumoral-administration-mediated combined cancer immunotherapy. (A) The intratumorally administered ZGd-NRs for combination therapy were supposed to release Zol and Gd3+, which depletes TAMs and induces RT-based ICD, respectively, leading to antitumor immunity activation. ZGd-NRs exhibited significant toxicity to both (B) cancer cells and (C) TAMs. (D) The intratumorally administered ZGd-NRs remained inside tumor tissues for a much longer time than the free ICGs (red dot circle and D: distant tumors, P: primary tumors). (E) The intratumoral administration of ZGd-NRs showed higher anticancer efficacy compared to the administration of Zol or Gd3+ alone, demonstrating the effectiveness of combination therapy. N.S. not significant, * p < 0.05, *** p < 0.001. Reproduced with permission [115]. Copyright 2017, ACS Publications.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 181

  1. Wakaskar, 2018, Promising effects of nanomedicine in cancer drug delivery, J. Drug Target., 26, 319, 10.1080/1061186X.2017.1377207 · DOI
  2. Stylianopoulos, 2013, EPR-effect: Utilizing size-dependent nanoparticle delivery to solid tumors, Ther. Deliv., 4, 421, 10.4155/tde.13.8 · DOI
  3. Ngoune, 2016, Accumulating nanoparticles by EPR: A route of no return, J. Control. Release, 238, 58, 10.1016/j.jconrel.2016.07.028 · DOI
  4. Greish, 2010, Enhanced permeability and retention (EPR) effect for anticancer nanomedicine drug targeting, Cancer Nanotechnol. Methods Protoc., 624, 25, 10.1007/978-1-60761-609-2_3 · DOI · Paper page
  5. Li, 2021, Recent advances in development of dendritic polymer-based nanomedicines for cancer diagnosis, Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol., 13, e1670, 10.1002/wnan.1670 · DOI
  6. Davis, 2008, Nanoparticle therapeutics: An emerging treatment modality for cancer, Nat. Rev. Drug Discov., 7, 771, 10.1038/nrd2614 · DOI · Paper page
  7. Blanchette, 2004, Nanoparticle and targeted systems for cancer therapy, Adv. Drug Deliv. Rev., 56, 1649, 10.1016/j.addr.2004.02.014 · DOI
  8. Hu, 2010, Nanoparticle-assisted combination therapies for effective cancer treatment, Ther. Deliv., 1, 323, 10.4155/tde.10.13 · DOI
  9. Wang, 2022, Strategies to improve the EPR effect: A mechanistic perspective and clinical translation, J. Control. Release, 345, 512, 10.1016/j.jconrel.2022.03.043 · DOI · Paper page
  10. Egusquiaguirre, 2012, Nanoparticle delivery systems for cancer therapy: Advances in clinical and preclinical research, Clin. Transl. Oncol., 14, 83, 10.1007/s12094-012-0766-6 · DOI
  11. Nichols, 2014, EPR: Evidence and fallacy, J. Control. Release, 190, 451, 10.1016/j.jconrel.2014.03.057 · DOI · Paper page
  12. He, 2019, Survey of clinical translation of cancer nanomedicines—Lessons learned from successes and failures, Acc. Chem. Res., 52, 2445, 10.1021/acs.accounts.9b00228 · DOI
  13. Danhier, 2016, To exploit the tumor microenvironment: Since the EPR effect fails in the clinic, what is the future of nanomedicine?, J. Control. Release, 244, 108, 10.1016/j.jconrel.2016.11.015 · DOI · Paper page
  14. Kreuter, 1991, Nanoparticle-based dmg delivery systems, J. Control. Release, 16, 169, 10.1016/0168-3659(91)90040-K · DOI
  15. Takemoto, 2008, Clinical toxicities of nanocarrier systems, Adv. Drug Deliv. Rev., 60, 929, 10.1016/j.addr.2007.11.007 · DOI · Paper page
  16. Byrne, 2008, Active targeting schemes for nanoparticle systems in cancer therapeutics, Adv. Drug Deliv. Rev., 60, 1615, 10.1016/j.addr.2008.08.005 · DOI
  17. Yoo, J., Park, C., Yi, G., Lee, D., and Koo, H. (2019). Active targeting strategies using biological ligands for nanoparticle drug delivery systems. Cancers, 11. · DOI
  18. Chu, 2019, Improving antitumor outcomes for palliative intratumoral injection therapy through lecithin–chitosan nanoparticles loading paclitaxel–cholesterol complex, Int. J. Nanomed., 14, 689, 10.2147/IJN.S188667 · DOI
  19. Moon, 2015, Nanoparticle approaches to combating drug resistance, Future Med. Chem., 7, 1503, 10.4155/fmc.15.82 · DOI
  20. Jia, 2012, Co-encapsulation of magnetic Fe3O4 nanoparticles and doxorubicin into biodegradable PLGA nanocarriers for intratumoral drug delivery, Int. J. Nanomed., 7, 1697
  21. Powell, 2010, Colloidal gold: A novel nanoparticle for targeted cancer therapeutics, Cancer Nanotechnol. Methods Protoc., 64, 375, 10.1007/978-1-60761-609-2_25 · DOI
  22. Brachi, 2020, Intratumoral injection of hydrogel-embedded nanoparticles enhances retention in glioblastoma, Nanoscale, 12, 23838, 10.1039/D0NR05053A · DOI
  23. Santini, 2017, Intravenous and intratumoral injection of Pluronic P94: The effect of administration route on biodistribution and tumor retention, Nanomed. Nanotechnol. Biol. Med., 13, 2179, 10.1016/j.nano.2017.04.015 · DOI
  24. Xie, 2012, Effect of intratumoral administration on biodistribution of 64Cu-labeled nanoshells, Int. J. Nanomed., 7, 2227, 10.2147/IJN.S30699 · DOI
  25. Kaffashi, 2017, Effects of curcumin-loaded PLGA nanoparticles on the RG2 rat glioma model, Mater. Sci. Eng. C, 78, 32, 10.1016/j.msec.2017.03.292 · DOI
  26. Jin, 2014, Encapsulating tantalum oxide into polypyrrole nanoparticles for X-ray CT/photoacoustic bimodal imaging-guided photothermal ablation of cancer, Biomaterials, 35, 5795, 10.1016/j.biomaterials.2014.03.086 · DOI
  27. Fukumura, 2007, Tumor microenvironment abnormalities: Causes, consequences, and strategies to normalize, J. Cell. Biochem., 101, 937, 10.1002/jcb.21187 · DOI · Paper page
  28. Danquah, 2011, Extravasation of polymeric nanomedicines across tumor vasculature, Adv. Drug Deliv. Rev., 63, 623, 10.1016/j.addr.2010.11.005 · DOI
  29. Jiang, 2020, Stroma-targeting therapy in pancreatic cancer: One coin with two sides?, Front. Oncol., 10, 576399, 10.3389/fonc.2020.576399 · DOI
  30. Rofstad, 2010, Associations between Radiocurability and Interstitial Fluid Pressure in Human Tumor Xenografts without Hypoxic TissueRadiocurability and Interstitial Fluid Pressure, Clin. Cancer Res., 16, 936, 10.1158/1078-0432.CCR-09-2718 · DOI
  31. Raju, 2008, High interstitial fluid pressure in rat tongue cancer is related to increased lymph vessel area, tumor size, invasiveness and decreased body weight, J. Oral Pathol. Med., 37, 137, 10.1111/j.1600-0714.2007.00602.x · DOI
  32. Gerstner, 2009, VEGF inhibitors in the treatment of cerebral edema in patients with brain cancer, Nat. Rev. Clin. Oncol., 6, 229, 10.1038/nrclinonc.2009.14 · DOI
  33. Sen, 2011, Mild Elevation of Body Temperature Reduces Tumor Interstitial Fluid Pressure and Hypoxia and Enhances Efficacy of Radiotherapy in Murine Tumor ModelsSystemic Heating Lowers Tumor IFP, Cancer Res., 71, 3872, 10.1158/0008-5472.CAN-10-4482 · DOI
  34. Pietras, 2003, PDGF receptors as cancer drug targets, Cancer Cell, 3, 439, 10.1016/S1535-6108(03)00089-8 · DOI
  35. Jain, 2002, Tumor angiogenesis and accessibility: Role of vascular endothelial growth factor, Semin. Oncol., 29, 3, 10.1053/sonc.2002.37265 · DOI
  36. Rippe, 1994, Transport of macromolecules across microvascular walls: The two-pore theory, Physiol. Rev., 74, 163, 10.1152/physrev.1994.74.1.163 · DOI
  37. Ernsting, 2013, Factors controlling the pharmacokinetics, biodistribution and intratumoral penetration of nanoparticles, J. Control. Release, 172, 782, 10.1016/j.jconrel.2013.09.013 · DOI
  38. Najafi, 2019, Extracellular matrix (ECM) stiffness and degradation as cancer drivers, J. Cell. Biochem., 120, 2782, 10.1002/jcb.27681 · DOI
  39. Miroshnikova, 2017, α5β1-Integrin promotes tension-dependent mammary epithelial cell invasion by engaging the fibronectin synergy site, Mol. Biol. Cell, 28, 2958, 10.1091/mbc.e17-02-0126 · DOI
  40. Leef, 2013, Molecular communication between tumor-associated fibroblasts and head and neck squamous cell carcinoma, Oral Oncol., 49, 381, 10.1016/j.oraloncology.2012.12.014 · DOI
  41. Cox, 2013, LOX-Mediated Collagen Crosslinking Is Responsible for Fibrosis-Enhanced MetastasisLOX, Fibrosis, and Metastasis, Cancer Res., 73, 1721, 10.1158/0008-5472.CAN-12-2233 · DOI · Paper page
  42. Zhang, 2011, Ovarian cancer-associated fibroblasts contribute to epithelial ovarian carcinoma metastasis by promoting angiogenesis, lymphangiogenesis and tumor cell invasion, Cancer Lett., 303, 47, 10.1016/j.canlet.2011.01.011 · DOI
  43. Denton, 2018, Stromal cells in the tumor microenvironment, Stromal Immunol., 1060, 99
  44. Tanaka, 2018, Stromal barriers to nanomedicine penetration in the pancreatic tumor microenvironment, Cancer Sci., 109, 2085, 10.1111/cas.13630 · DOI
  45. Jackson, 2007, Magnetic resonance imaging of therapy-induced necrosis using gadolinium-chelated polyglutamic acids, Int. J. Radiat. Oncol. Biol. Phys., 68, 830, 10.1016/j.ijrobp.2007.01.011 · DOI
  46. Li, 2013, Deep penetration of nanoparticulate drug delivery systems into tumors: Challenges and solutions, Curr. Med. Chem., 20, 2881, 10.2174/09298673113209990004 · DOI
  47. Roy, 2015, A highly tumor-targeted nanoparticle of podophyllotoxin penetrated tumor core and regressed multidrug resistant tumors, Biomaterials, 52, 335, 10.1016/j.biomaterials.2015.02.041 · DOI
  48. Zhang, 2019, Strategies to improve tumor penetration of nanomedicines through nanoparticle design, Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol., 11, e1519, 10.1002/wnan.1519 · DOI
  49. Hu, 2021, The progress and perspective of strategies to improve tumor penetration of nanomedicines, Chin. Chem. Lett., 32, 1341, 10.1016/j.cclet.2020.11.006 · DOI
  50. Gaumet, 2008, Nanoparticles for drug delivery: The need for precision in reporting particle size parameters, Eur. J. Pharm. Biopharm., 69, 1, 10.1016/j.ejpb.2007.08.001 · DOI
  51. Blanco, 2015, Principles of nanoparticle design for overcoming biological barriers to drug delivery, Nat. Biotechnol., 33, 941, 10.1038/nbt.3330 · DOI · Paper page
  52. Wang, 1998, Intratumoral injection of rhenium-188 microspheres into an animal model of hepatoma, J. Nucl. Med., 39, 1752
  53. Bakker, 2018, Intratumoral injection of radioactive holmium (166Ho) microspheres for treatment of oral squamous cell carcinoma in cats, Vet. Comp. Oncol., 16, 114, 10.1111/vco.12319 · DOI
  54. Bakker, 2018, Intratumoral injection of radioactive holmium-166 microspheres in recurrent head and neck squamous cell carcinoma: Preliminary results of first use, Nucl. Med. Commun., 39, 213, 10.1097/MNM.0000000000000792 · DOI
  55. Dreher, 2006, Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers, J. Natl. Cancer Inst., 98, 335, 10.1093/jnci/djj070 · DOI
  56. Liu, 2010, A nanoparticle size series for in vivo fluorescence imaging, Angew. Chem., 122, 8831, 10.1002/ange.201003142 · DOI
  57. Goodman, 2008, Spatio-temporal modeling of nanoparticle delivery to multicellular tumor spheroids, Biotechnol. Bioeng., 101, 388, 10.1002/bit.21910 · DOI
  58. Tanaka, 2005, Intratumoral injection of immature dendritic cells enhances antitumor effect of hyperthermia using magnetic nanoparticles, Int. J. Cancer, 116, 624, 10.1002/ijc.21061 · DOI
  59. Cho, 2010, The effects of size, shape, and surface functional group of gold nanostructures on their adsorption and internalization by cells, Small, 6, 517, 10.1002/smll.200901622 · DOI
  60. Sohrabi Kashani, A., and Packirisamy, M. (2021). Cancer-Nano-Interaction: From Cellular Uptake to Mechanobiological Responses. Int. J. Mol. Sci., 22. · DOI
  61. Durymanov, 2015, Current approaches for improving intratumoral accumulation and distribution of nanomedicines, Theranostics, 5, 1007, 10.7150/thno.11742 · DOI
  62. Chauhan, 2011, Fluorescent nanorods and nanospheres for real-time in vivo probing of nanoparticle shape-dependent tumor penetration, Angew. Chem. Int. Ed., 50, 11417, 10.1002/anie.201104449 · DOI
  63. Black, 2014, Radioactive 198Au-doped nanostructures with different shapes for in vivo analyses of their biodistribution, tumor uptake, and intratumoral distribution, ACS Nano, 8, 4385, 10.1021/nn406258m · DOI
  64. Debotton, 2007, Targeting of nanoparticles to the clathrin-mediated endocytic pathway, Biochem. Biophys. Res. Commun., 353, 26, 10.1016/j.bbrc.2006.11.135 · DOI
  65. Salatin, 2015, Effect of the surface modification, size, and shape on cellular uptake of nanoparticles, Cell Biol. Int., 39, 881, 10.1002/cbin.10459 · DOI
  66. Campbell, 2002, Cationic charge determines the distribution of liposomes between the vascular and extravascular compartments of tumors, Cancer Res., 62, 6831
  67. Kim, 2010, Tuning payload delivery in tumour cylindroids using gold nanoparticles, Nat. Nanotechnol., 5, 465, 10.1038/nnano.2010.58 · DOI
  68. Priwitaningrum, 2016, Tumor stroma-containing 3D spheroid arrays: A tool to study nanoparticle penetration, J. Control. Release, 244, 257, 10.1016/j.jconrel.2016.09.004 · DOI
  69. Jokerst, 2011, Nanoparticle PEGylation for imaging and therapy, Nanomedicine, 6, 715, 10.2217/nnm.11.19 · DOI
  70. Suk, 2016, PEGylation as a strategy for improving nanoparticle-based drug and gene delivery, Adv. Drug Deliv. Rev., 99, 28, 10.1016/j.addr.2015.09.012 · DOI · Paper page
  71. Mishra, 2016, PEGylation in anti-cancer therapy: An overview, Asian J. Pharm. Sci., 11, 337, 10.1016/j.ajps.2015.08.011 · DOI
  72. Bevilacqua, P., Nuzzo, S., Torino, E., Condorelli, G., Salvatore, M., and Grimaldi, A.M. (2021). Antifouling strategies of nanoparticles for diagnostic and therapeutic application: A systematic review of the literature. Nanomaterials, 11. · DOI
  73. Lieleg, 2009, Selective filtering of particles by the extracellular matrix: An electrostatic bandpass, Biophys. J., 97, 1569, 10.1016/j.bpj.2009.07.009 · DOI
  74. Soenen, 2014, The cellular interactions of PEGylated gold nanoparticles: Effect of PEGylation on cellular uptake and cytotoxicity, Part. Part. Syst. Charact., 31, 794, 10.1002/ppsc.201300357 · DOI
  75. Ferrari, 2014, Investigation of size, surface charge, PEGylation degree and concentration on the cellular uptake of polymer nanoparticles, Colloids Surf. B Biointerfaces, 123, 639, 10.1016/j.colsurfb.2014.10.003 · DOI
  76. Chattopadhyay, 2012, Role of antibody-mediated tumor targeting and route of administration in nanoparticle tumor accumulation in vivo, Mol. Pharm., 9, 2168, 10.1021/mp300016p · DOI
  77. Lin, 2015, Self-targeted, bacillus-shaped, and controlled-release methotrexate prodrug polymeric nanoparticles for intratumoral administration with improved therapeutic efficacy in tumor-bearing mice, J. Mater. Chem. B, 3, 7707, 10.1039/C5TB00724K · DOI
  78. Ruoslahti, 2017, Tumor penetrating peptides for improved drug delivery, Adv. Drug Deliv. Rev., 110, 3, 10.1016/j.addr.2016.03.008 · DOI
  79. Teesalu, 2013, Tumor-penetrating peptides, Front. Oncol., 3, 216, 10.3389/fonc.2013.00216 · DOI
  80. Chen, 2013, Application of a Proapoptotic Peptide to Intratumorally Spreading Cancer TherapyIntratumorally Spreading Tumor Therapy, Cancer Res., 73, 1352, 10.1158/0008-5472.CAN-12-1979 · DOI
  81. Feron, 2010, Tumor-penetrating peptides: A shift from magic bullets to magic guns, Sci. Transl. Med., 2, 34ps26, 10.1126/scitranslmed.3001174 · DOI
  82. Dahaghin, 2021, A comparative study on the effects of increase in injection sites on the magnetic nanoparticles hyperthermia, J. Drug Deliv. Sci. Technol., 63, 102542, 10.1016/j.jddst.2021.102542 · DOI
  83. Subbotin, 2019, Modeling multi-needle injection into solid tumor, Am. J. Cancer Res., 9, 2209
  84. Willink, 2023, Intratumoral injection therapies for locally advanced pancreatic cancer: Systematic review, BJS Open, 7, zrad052, 10.1093/bjsopen/zrad052 · DOI
  85. Bult, W., Kroeze, S.G., Elschot, M., Seevinck, P.R., Beekman, F.J., de Jong, H.W., Uges, D.R., Kosterink, J.G., Luijten, P.R., and Hennink, W.E. (2013). Intratumoral administration of holmium-166 acetylacetonate microspheres: Antitumor efficacy and feasibility of multimodality imaging in renal cancer. PLoS ONE, 8. · DOI
  86. Shevtsov, 2014, Pilot study of intratumoral injection of recombinant heat shock protein 70 in the treatment of malignant brain tumors in children, OncoTargets Ther., 7, 1071, 10.2147/OTT.S62764 · DOI
  87. Chen, 2006, A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma, Ann. Surg., 243, 321, 10.1097/01.sla.0000201480.65519.b8 · DOI
  88. Tselikas, 2021, Interventional radiology for local immunotherapy in oncology, Clin. Cancer Res., 27, 2698, 10.1158/1078-0432.CCR-19-4073 · DOI
  89. Lau, 2000, Local ablative therapy for hepatocellular carcinoma, Endoscopy, 32, 644, 10.1055/s-2000-4664 · DOI
  90. Li, 2014, Interventional therapy for human breast cancer in nude mice with 131I gelatin microspheres (131I-GMSs) following intratumoral injection, Radiat. Oncol., 9, 144, 10.1186/1748-717X-9-144 · DOI
  91. Pacheco, 2023, Recent advances in long-acting drug delivery systems for anticancer drug, Adv. Drug Deliv. Rev., 194, 114724, 10.1016/j.addr.2023.114724 · DOI
  92. Kim, J., Choi, Y., Yang, S., Lee, J., Choi, J., Moon, Y., Kim, J., Shim, N., Cho, H., and Shim, M.K. (2022). Sustained and Long-Term Release of Doxorubicin from PLGA Nanoparticles for Eliciting Anti-Tumor Immune Responses. Pharmaceutics, 14. · DOI
  93. Zhao, 2019, Thermosensitive nanogels with cross-linked Pd (II) ions for improving therapeutic effects on platinum-resistant cancers via intratumoral formation of hydrogels, Chem. Mater., 31, 5089, 10.1021/acs.chemmater.9b00986 · DOI
  94. Lan, 2018, Microneedle-mediated delivery of lipid-coated cisplatin nanoparticles for efficient and safe cancer therapy, ACS Appl. Mater. Interfaces, 10, 33060, 10.1021/acsami.8b12926 · DOI
  95. Yi, 2010, Matrix metalloproteinase sensitive gold nanorod for simultaneous bioimaging and photothermal therapy of cancer, Bioconjugate Chem., 21, 2173, 10.1021/bc100308p · DOI
  96. Zhang, 2019, Acid-triggered in situ aggregation of gold nanoparticles for multimodal tumor imaging and photothermal therapy, ACS Biomater. Sci. Eng., 5, 1589, 10.1021/acsbiomaterials.8b01623 · DOI
  97. Wang, 2020, Designing immunogenic nanotherapeutics for photothermal-triggered immunotherapy involving reprogramming immunosuppression and activating systemic antitumor responses, Biomaterials, 255, 120153, 10.1016/j.biomaterials.2020.120153 · DOI
  98. Lucky, 2015, Titania coated upconversion nanoparticles for near-infrared light triggered photodynamic therapy, ACS Nano, 9, 191, 10.1021/nn503450t · DOI
  99. Wang, 2011, Near-infrared light induced in vivo photodynamic therapy of cancer based on upconversion nanoparticles, Biomaterials, 32, 6145, 10.1016/j.biomaterials.2011.05.007 · DOI
  100. Petriev, 2019, Nuclear nanomedicine using Si nanoparticles as safe and effective carriers of 188Re radionuclide for cancer therapy, Sci. Rep., 9, 2017, 10.1038/s41598-018-38474-7 · DOI
  101. Gong, 2018, Core–shell TaOx@MnO2 nanoparticles as a nano-radiosensitizer for effective cancer radiotherapy, J. Mater. Chem. B, 6, 2250, 10.1039/C8TB00070K · DOI
  102. Huang, 2021, Zoledronic Acid–Gadolinium Coordination Polymer Nanorods for Improved Tumor Radioimmunotherapy by Synergetically Inducing Immunogenic Cell Death and Reprogramming the Immunosuppressive Microenvironment, ACS Nano, 15, 8450, 10.1021/acsnano.0c10764 · DOI
  103. Guo, 2014, Combinatorial photothermal and immuno cancer therapy using chitosan-coated hollow copper sulfide nanoparticles, ACS Nano, 8, 5670, 10.1021/nn5002112 · DOI
  104. Noh, 2010, Pegylated poly-l-arginine derivatives of chitosan for effective delivery of siRNA, J. Control. Release, 145, 159, 10.1016/j.jconrel.2010.04.005 · DOI
  105. Ngamcherdtrakul, 2021, In situ tumor vaccination with nanoparticle co-delivering CpG and STAT3 siRNA to effectively induce whole-body antitumor immune response, Adv. Mater., 33, 2100628, 10.1002/adma.202100628 · DOI
  106. He, Q., Zhou, L., Yu, D., Zhu, R., Chen, Y., Song, M., Liu, X., Liao, Y., Ding, T., and Fan, W. (2023). Near-Infrared-Activatable PROTAC Nanocages for Controllable Target Protein Degradation and On-Demand Antitumor Therapy. J. Med. Chem. · DOI
  107. Li, 2023, c-Myc-Targeting PROTAC Based on a TNA-DNA Bivalent Binder for Combination Therapy of Triple-Negative Breast Cancer, J. Am. Chem. Soc., 145, 9334, 10.1021/jacs.3c02619 · DOI
  108. Deng, 2013, Layer-by-layer nanoparticles for systemic codelivery of an anticancer drug and siRNA for potential triple-negative breast cancer treatment, ACS Nano, 7, 9571, 10.1021/nn4047925 · DOI
  109. Gao, 2021, Intratumoral administration of thermosensitive hydrogel co-loaded with norcantharidin nanoparticles and doxorubicin for the treatment of hepatocellular carcinoma, Int. J. Nanomed., 16, 4073, 10.2147/IJN.S308057 · DOI
  110. Kwon, 2016, Synergistic anti-tumor activity through combinational intratumoral injection of an in-situ injectable drug depot, Biomaterials, 85, 232, 10.1016/j.biomaterials.2016.02.001 · DOI
  111. Ma, 2015, Drug coated microneedles for minimally-invasive treatment of oral carcinomas: Development and in vitro evaluation, Biomed. Microdevices, 17, 44, 10.1007/s10544-015-9944-y · DOI
  112. Bhatnagar, 2019, Dissolvable microneedle patch containing doxorubicin and docetaxel is effective in 4T1 xenografted breast cancer mouse model, Int. J. Pharm., 556, 263, 10.1016/j.ijpharm.2018.12.022 · DOI
  113. Li, 2016, Designing hydrogels for controlled drug delivery, Nat. Rev. Mater., 1, 16071, 10.1038/natrevmats.2016.71 · DOI
  114. Tiwari, 2018, pH/NIR-responsive polypyrrole-functionalized fibrous localized drug-delivery platform for synergistic cancer therapy, ACS Appl. Mater. Interfaces, 10, 20256, 10.1021/acsami.7b17664 · DOI
  115. Prausnitz, 2004, Microneedles for transdermal drug delivery, Adv. Drug Deliv. Rev., 56, 581, 10.1016/j.addr.2003.10.023 · DOI
  116. Indermun, 2014, Current advances in the fabrication of microneedles for transdermal delivery, J. Control. Release, 185, 130, 10.1016/j.jconrel.2014.04.052 · DOI
  117. Chen, 2018, In vitro and in vivo assessment of polymer microneedles for controlled transdermal drug delivery, J. Drug Target., 26, 720, 10.1080/1061186X.2018.1424859 · DOI
  118. Chen, 2018, Controlled Delivery of Insulin Using Rapidly Separating Microneedles Fabricated from Genipin-Crosslinked Gelatin, Macromol. Rapid Commun., 39, 1800075, 10.1002/marc.201800075 · DOI
  119. Puolakkainen, 1991, Contact Nd: YAG laser potentiates the tumor cell killing effect of hyperthermia, Lasers Surg. Med., 11, 595, 10.1002/lsm.1900110615 · DOI
  120. Waldow, 1988, Nd: YAG laser-induced hyperthermia in a mouse tumor model, Lasers Surg. Med., 8, 510, 10.1002/lsm.1900080510 · DOI
  121. Yun, W.S., Shim, M.K., Lim, S., Song, S., Kim, J., Yang, S., Hwang, H.S., Kim, M.R., Yoon, H.Y., and Lim, D.-K. (2022). Mesenchymal Stem Cell-Mediated Deep Tumor Delivery of Gold Nanorod for Photothermal Therapy. Nanomaterials, 12. · DOI
  122. Marmor, 1979, Treatment of superficial human neoplasms by local hyperthermia induced by ultrasound, Cancer, 43, 188, 10.1002/1097-0142(197901)43:1<188::AID-CNCR2820430128>3.0.CO;2-7 · DOI
  123. Seki, 1999, Percutaneous microwave coagulation therapy for patients with small hepatocellular carcinoma: Comparison with percutaneous ethanol injection therapy, Cancer Interdiscip. Int. J. Am. Cancer Soc., 85, 1694
  124. Ash, 2017, Effect of wavelength and beam width on penetration in light-tissue interaction using computational methods, Lasers Med. Sci., 32, 1909, 10.1007/s10103-017-2317-4 · DOI · Paper page
  125. Link, 1999, Laser photothermal melting and fragmentation of gold nanorods: Energy and laser pulse-width dependence, J. Phys. Chem. A, 103, 1165, 10.1021/jp983141k · DOI
  126. Huang, 2006, Selective laser photo-thermal therapy of epithelial carcinoma using anti-EGFR antibody conjugated gold nanoparticles, Cancer Lett., 239, 129, 10.1016/j.canlet.2005.07.035 · DOI
  127. Ke, 2014, Gold nanoshelled liquid perfluorocarbon nanocapsules for combined dual modal ultrasound/CT imaging and photothermal therapy of cancer, Small, 10, 1220, 10.1002/smll.201302252 · DOI
  128. Liu, 2015, A plasmonic gold nanostar theranostic probe for in vivo tumor imaging and photothermal therapy, Theranostics, 5, 946, 10.7150/thno.11974 · DOI
  129. Link, 2005, Simulation of the optical absorption spectra of gold nanorods as a function of their aspect ratio and the effect of the medium dielectric constant, J. Phys. Chem. B, 109, 10531, 10.1021/jp058091f · DOI
  130. Xu, 2018, PEGylated hydrazided gold nanorods for pH-triggered chemo/photodynamic/photothermal triple therapy of breast cancer, Acta Biomater., 82, 171, 10.1016/j.actbio.2018.10.019 · DOI
  131. Hwang, 2022, Escherichia coli mimetic gold nanorod-mediated photo-and immunotherapy for treating cancer and its metastasis, ACS Nano, 16, 8472, 10.1021/acsnano.2c03379 · DOI
  132. Rengan, 2014, Multifunctional gold coated thermo-sensitive liposomes for multimodal imaging and photo-thermal therapy of breast cancer cells, Nanoscale, 6, 916, 10.1039/C3NR04448C · DOI
  133. Melamed, 2015, Elucidating the fundamental mechanisms of cell death triggered by photothermal therapy, ACS Nano, 9, 6, 10.1021/acsnano.5b00021 · DOI
  134. Pelaz, 2012, Tailoring the synthesis and heating ability of gold nanoprisms for bioapplications, Langmuir, 28, 8965, 10.1021/la204712u · DOI
  135. Mitchell, 2015, Dissecting the molecular mechanism of apoptosis during photothermal therapy using gold nanoprisms, ACS Nano, 9, 52, 10.1021/nn505468v · DOI
  136. Nam, 2018, Chemo-photothermal therapy combination elicits anti-tumor immunity against advanced metastatic cancer, Nat. Commun., 9, 1074, 10.1038/s41467-018-03473-9 · DOI · Paper page
  137. Ma, 2019, Near-infrared II phototherapy induces deep tissue immunogenic cell death and potentiates cancer immunotherapy, ACS Nano, 13, 11967, 10.1021/acsnano.9b06040 · DOI
  138. Feng, 2021, A combination strategy based on an Au nanorod/doxorubicin gel via mild photothermal therapy combined with antigen-capturing liposomes and anti-PD-L1 agent promote a positive shift in the cancer-immunity cycle, Acta Biomater., 136, 495, 10.1016/j.actbio.2021.09.052 · DOI
  139. Zhao, 2021, Recent advances in selective photothermal therapy of tumor, J. Nanobiotechnol., 19, 335, 10.1186/s12951-021-01080-3 · DOI
  140. Allison, 2013, Photodynamic therapy (PDT): PDT mechanisms, Clin. Endosc., 46, 24, 10.5946/ce.2013.46.1.24 · DOI
  141. Baptista, 2017, Type I and type II photosensitized oxidation reactions: Guidelines and mechanistic pathways, Photochem. Photobiol., 93, 912, 10.1111/php.12716 · DOI
  142. Li, 2022, Type I AIE photosensitizers: Mechanism and application, View, 3, 20200121, 10.1002/VIW.20200121 · DOI
  143. Cheng, 2014, Functional nanomaterials for phototherapies of cancer, Chem. Rev., 114, 10869, 10.1021/cr400532z · DOI
  144. Huang, 2008, Photodynamic therapy for treatment of solid tumors—Potential and technical challenges, Technol. Cancer Res. Treat., 7, 309, 10.1177/153303460800700405 · DOI
  145. Chen, 2008, Nanoparticle self-lighting photodynamic therapy for cancer treatment, J. Biomed. Nanotechnol., 4, 369, 10.1166/jbn.2008.001 · DOI
  146. Deng, 2017, Recent progress in near infrared light triggered photodynamic therapy, Small, 13, 1702299, 10.1002/smll.201702299 · DOI
  147. Yuan, 2013, Application of near-infrared dyes for tumor imaging, photothermal, and photodynamic therapies, J. Pharm. Sci., 102, 6, 10.1002/jps.23356 · DOI
  148. Breskey, 2013, Photodynamic therapy: Occupational hazards and preventative recommendations for clinical administration by healthcare providers, Photomed. Laser Surg., 31, 398, 10.1089/pho.2013.3496 · DOI
  149. Paszko, 2011, Nanodrug applications in photodynamic therapy, Photodiagn. Photodyn. Ther., 8, 14, 10.1016/j.pdpdt.2010.12.001 · DOI
  150. Gu, 2023, Enzyme-triggered deep tumor penetration of a dual-drug nanomedicine enables an enhanced cancer combination therapy, Bioact. Mater., 26, 102, 10.1016/j.bioactmat.2023.02.015 · DOI
  151. Song, 2017, Emerging nanotechnology and advanced materials for cancer radiation therapy, Adv. Mater., 29, 1700996, 10.1002/adma.201700996 · DOI
  152. Martins, 2018, Radioimmunotherapy for delivery of cytotoxic radioisotopes: Current status and challenges, Expert Opin. Drug Deliv., 15, 185, 10.1080/17425247.2018.1378180 · DOI
  153. Pei, 2021, Biomaterial-mediated internal radioisotope therapy, Mater. Horiz., 8, 1348, 10.1039/D0MH01761B · DOI
  154. Clement, 2020, Mechanisms for tuning engineered nanomaterials to enhance radiation therapy of cancer, Adv. Sci., 7, 2003584, 10.1002/advs.202003584 · DOI
  155. Nigro, 1974, Combined therapy for cancer of the anal canal: A preliminary report, Dis. Colon Rectum, 17, 354, 10.1007/BF02586980 · DOI
  156. Carrick, 2009, Single agent versus combination chemotherapy for metastatic breast cancer, Cochrane Database Syst. Rev., 2, 1
  157. Mokhtari, 2017, Combination therapy in combating cancer, Oncotarget, 8, 38022, 10.18632/oncotarget.16723 · DOI · Paper page
  158. Vanneman, 2012, Combining immunotherapy and targeted therapies in cancer treatment, Nat. Rev. Cancer, 12, 237, 10.1038/nrc3237 · DOI
  159. Esfahani, 2020, A review of cancer immunotherapy: From the past, to the present, to the future, Curr. Oncol., 27, 87, 10.3747/co.27.5223 · DOI
  160. Wang, 2018, Combining immunotherapy and radiotherapy for cancer treatment: Current challenges and future directions, Front. Pharmacol., 9, 185, 10.3389/fphar.2018.00185 · DOI
  161. Nam, 2019, Cancer nanomedicine for combination cancer immunotherapy, Nat. Rev. Mater., 4, 398, 10.1038/s41578-019-0108-1 · DOI
  162. Apetoh, 2015, Combining immunotherapy and anticancer agents: The right path to achieve cancer cure?, Ann. Oncol., 26, 1813, 10.1093/annonc/mdv209 · DOI
  163. Hu, 2012, Nanoparticle-based combination therapy toward overcoming drug resistance in cancer, Biochem. Pharmacol., 83, 1104, 10.1016/j.bcp.2012.01.008 · DOI
  164. Xu, 2015, Cancer nanomedicine: From targeted delivery to combination therapy, Trends Mol. Med., 21, 223, 10.1016/j.molmed.2015.01.001 · DOI · Paper page
  165. Lee, 2016, Delivery strategies and potential targets for siRNA in major cancer types, Adv. Drug Deliv. Rev., 104, 2, 10.1016/j.addr.2016.05.010 · DOI
  166. Gewirtz, 2007, On future’s doorstep: RNA interference and the pharmacopeia of tomorrow, J. Clin. Investig., 117, 3612, 10.1172/JCI34274 · DOI
  167. Huang, 2016, Pharmacokinetic behaviors of intravenously administered siRNA in glandular tissues, Theranostics, 6, 1528, 10.7150/thno.15246 · DOI
  168. Gavrilov, 2012, Therapeutic siRNA: Principles, challenges, and strategies, Yale J. Biol. Med., 85, 187
  169. Tatiparti, K., Sau, S., Kashaw, S.K., and Iyer, A.K. (2017). siRNA delivery strategies: A comprehensive review of recent developments. Nanomaterials, 7. · DOI
  170. Oh, 2009, siRNA delivery systems for cancer treatment, Adv. Drug Deliv. Rev., 61, 850, 10.1016/j.addr.2009.04.018 · DOI
  171. Pan, 2015, New paradigms on siRNA local application, BMB Rep., 48, 147, 10.5483/BMBRep.2015.48.3.089 · DOI
  172. Zou, 2019, The PROTAC technology in drug development, Cell Biochem. Funct., 37, 21, 10.1002/cbf.3369 · DOI
  173. Paiva, 2019, Targeted protein degradation: Elements of PROTAC design, Curr. Opin. Chem. Biol., 50, 111, 10.1016/j.cbpa.2019.02.022 · DOI
  174. Chen, 2022, Proteolysis-targeting chimera (PROTAC) delivery system: Advancing protein degraders towards clinical translation, Chem. Soc. Rev., 51, 5330, 10.1039/D1CS00762A · DOI
  175. Moon, Y., Jeon, S.I., Shim, M.K., and Kim, K. (2023). Cancer-specific delivery of proteolysis-targeting chimeras (PROTACs) and their application to cancer immunotherapy. Pharmaceutics, 15. · DOI
  176. Thapa, 2023, Nanomedicine-based commercial formulations: Current developments and future prospects, J. Pharm. Investig., 53, 19, 10.1007/s40005-022-00607-6 · DOI
  177. Wilson, 2021, Facile bioinspired synthesis of iron oxide encapsulating silica nanocapsules, J. Colloid Interface Sci., 601, 78, 10.1016/j.jcis.2021.05.021 · DOI
  178. Rodríguez, F., Caruana, P., De la Fuente, N., Español, P., Gámez, M., Balart, J., Llurba, E., Rovira, R., Ruiz, R., and Martín-Lorente, C. (2022). Nano-based approved pharmaceuticals for cancer treatment: Present and future challenges. Biomolecules, 12. · DOI
  179. Anselmo, 2019, Nanoparticles in the clinic: An update, Bioeng. Transl. Med., 4, e10143, 10.1002/btm2.10143 · DOI · Paper page
  180. Bonvalot, 2019, NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act. In. Sarc): A multicentre, phase 2–3, randomised, controlled trial, Lancet Oncol., 20, 1148, 10.1016/S1470-2045(19)30326-2 · DOI
  181. Bonvalot, 2017, First-in-human study testing a new radioenhancer using nanoparticles (NBTXR3) activated by radiation therapy in patients with locally advanced soft tissue sarcomas, Clin. Cancer Res., 23, 908, 10.1158/1078-0432.CCR-16-1297 · DOI · Paper page

Cited by

Sorted by citations

See all 76

Metadata

Authors
Yun, W. S., Kim, J., Lim, D.-K., Kim, D.-H., Jeon, S. I., & Kim, K.
Venue
Nanomaterials
Publisher
MDPI AG
Published
2023-07-31
Volume
13
Issue
15
Pages
2225
ISSN
2079-4991
DOI
10.3390/nano13152225
PMC
PMC10421122
Cited by
76
References
14
Language
en
Licence
creativecommons.org/licenses/by/4.0/ (vor)
Funders
National Research Foundation (NRF) of Korea (NRF-2022M3H4A1A03067401)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review